The goal of this clinical trial is to learn if drug hydrolyzed lignin works to treat H pylori infection in adults. It will also learn about the safety of drug lignin n the sitting of H pylori infection, and if it halts the side effects associated with H pylori triple therapy. The main questions it aims to answer are:

• Does drug hydrolyzed lignin improve the H pylori eradiation rate when it is added to the standard triple therapy used in treatment of H pylori?
• What medical problems do participants experience when taking drug hydrolyzed lignin? Researchers will compare drug hydrolyzed lignin to a placebo (a look-alike substance that contains no drug) to see if drug hydrolyzed lignin works to treat H pylori.

Participants will:

• Take drug hydrolyzed lignin or a placebo every day for 2 weeks beside the standard triple therapy
• Visit the clinic once every 1 week for checkup and questionnaire filling
• Check for H pylori eradication after treatment

Inclusion Criteria:

• Age: Adults, older than 18.
• Gender: all
• Patient with confirmed diagnosis of H pylori for the first time
• H pylori treatment naive patients
• Welling to participate

Exclusion Criteria:

• Patients with failed H pylori eradication
• Allergy to the used medications
• Patients with other structural bowel diseases e.g. celiac disease, ischemic colitis, IBD, chronic diarrhea
• General debilitating diseases e.g. decompensated cirrhosis, renal failure